Search results
Results from the WOW.Com Content Network
The incidence of TA-GvHD in immunocompromised patients receiving blood transfusions is estimated to be 0.1–1.0%, and mortality around 80–90%. Mortality is higher in TA-GvHD than in GvHD associated with bone marrow transplantation , where the engrafted lymphoid cells in the bone marrow are of donor origin (in autotransplant) and therefore ...
Some research studies have shown that, because of this immune depression, blood transfusions increase the risk of infections and cancer recurrence. However, other studies have not shown these differences and the degree of impact transfusion has on infection and tumor recurrence is not well understood. [ 2 ]
The prevalence of AHTR has been estimated at 1 in 70,000 blood transfusions, whereas the prevalence of DHTR is thought to be underreported, although various studies estimate the prevalence of DHTR as between 1 in 800, to 1 in 11,000 transfusions. [1] Hemolytic transfusion reactions are a possible complication from red blood cell transfusions.
An acute hemolytic transfusion reaction (AHTR), also called immediate hemolytic transfusion reaction, is a life-threatening reaction to receiving a blood transfusion. AHTRs occur within 24 hours of the transfusion and can be triggered by a few milliliters of blood. The reaction is triggered by host antibodies destroying donor red blood cells.
The risk of severe bacterial infection is estimated, as of 2020, at about 1 in 2,500 platelet transfusions, and 1 in 2,000,000 red blood cell transfusions. [44] Blood product contamination, while rare, is still more common than actual infection.
The site began in 1998 as a pen and paper questionnaire called the Harvard Cancer Risk Index. [2] In January 2000, The Harvard Cancer Risk Index developed into an online assessment and was renamed Your Cancer Risk, and offered assessments for four cancers: breast, colon, lung, and prostate. Six months later, eight additional cancers were added. [3]
Transfusion hemosiderosis can cause permanent damage to tissues that may lead to death. [2] Tissue damage can remain even after chelation therapy. [2] Outcomes are usually worse in patients who require blood transfusions compared to those who can have alternative therapies. [2] Cardiomyopathy and cardiac arrhythmia are often a cause of death. [1]
Transfusion-dependent anemia is a form of anemia characterized by the need for continuous blood transfusion. It is a condition that results from various diseases, and is associated with decreased survival rates. [1] [2] Regular transfusion is required to reduce the symptoms of anemia by increasing functional red blood cells and hemoglobin count.